0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover683.98%IV-194.12%PremiumAug 16, 2024Expiry Date3.30Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.3839Delta0.1260Gamma0.43Leverage Ratio-0.0231Theta-0.0023Rho-0.16Eff Leverage0.0017Vega
Coherus BioSciences Stock Discussion
Coherus BioSciences Inc - Apotex Agreed to Pay to Company an Upfront Payment of $6.25 Mln United States Dollars under license agreement
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
HODL to the Moon.
Chs-114 Shown to Have Acceptable Safety Profile With No Dose-Limiting Toxicities in Heavily Pretreated Patients With Solid Tumors
NEWS
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Coherus BioSciences announced preliminary Phase 1 results for CHS-114, an anti-CCR8 antibody, at the 2024 ASCO Annual Meeting. CHS-114 exhibited an acceptable safety profile with no dose-limiting toxicities in heavily pretreated patients with solid tumors. Sele...
NEWS
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
Coherus BioSciences, Inc. announced a clinical collaboration with the Cancer Research Institute (CRI) to explore a combination of LOQTORZI (toripalimab-tpzi) with ENB-003 for the treatment of ovarian cancer. The iPROC platform study aims to investigate the ...
Dow Jones· 5 mins ago
No comment yet